Welcome to LookChem.com Sign In|Join Free
  • or
Salfluverine is a medication primarily used to treat gastrointestinal disorders, such as functional dyspepsia and irritable bowel syndrome. It is a selective 5-HT4 receptor agonist, which means it stimulates the 5-HT4 receptors in the gut, promoting the release of acetylcholine and enhancing gastrointestinal motility. This action helps to alleviate symptoms like bloating, abdominal pain, and discomfort associated with these conditions. Salfluverine is typically taken orally and is well-tolerated, with minimal side effects. It is an effective treatment option for patients suffering from gastrointestinal motility issues, improving their quality of life by reducing symptoms and promoting a more regular digestive system.

587-49-5

Post Buying Request

587-49-5 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

587-49-5 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 587-49-5 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 5,8 and 7 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 587-49:
(5*5)+(4*8)+(3*7)+(2*4)+(1*9)=95
95 % 10 = 5
So 587-49-5 is a valid CAS Registry Number.
InChI:InChI=1/C14H10F3NO2/c15-14(16,17)9-4-3-5-10(8-9)18-13(20)11-6-1-2-7-12(11)19/h1-8,19H,(H,18,20)

587-49-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 12, 2017

Revision Date: Aug 12, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-hydroxy-N-[3-(trifluoromethyl)phenyl]benzamide

1.2 Other means of identification

Product number -
Other names 2-Hydroxy-N-(3-(trifluoromethyl)phenyl)benzamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:587-49-5 SDS

587-49-5Downstream Products

587-49-5Relevant academic research and scientific papers

Discovery and Structure Relationships of Salicylanilide Derivatives as Potent, Non-acidic P2X1 Receptor Antagonists

Tian, Maoqun,Abdelrahman, Aliaa,Baqi, Younis,Fuentes, Eduardo,Azazna, Djamil,Spanier, Claudia,Densborn, Sabrina,Hinz, Sonja,Schmid, Ralf,Müller, Christa E.

, p. 6164 - 6178 (2020/07/10)

Antagonists for the ATP-gated ion channel receptor P2X1 have potential as antithrombotics and for treating hyperactive bladder and inflammation. In this study, salicylanilide derivatives were synthesized based on a screening hit. P2X1 antagonistic potency was assessed in 1321N1 astrocytoma cells stably transfected with the human P2X1 receptor by measuring inhibition of the ATP-induced calcium influx. Structure-activity relationships were analyzed, and selectivity versus other P2X receptor subtypes was assessed. The most potent compounds, N-[3,5-bis(trifluoromethyl)phenyl]-5-chloro-2-hydroxybenzamide (1, IC50 0.0192 μM) and N-[3,5-bis(trifluoromethyl)phenyl]-4-chloro-2-hydroxybenzamide (14, IC50 0.0231 μM), displayed >500-fold selectivity versus P2X2 and P2X3, and 10-fold selectivity versus P2X4 and P2X7 receptors, and inhibited collagen-induced platelet aggregation. They behaved as negative allosteric modulators, and molecular modeling studies suggested an extracellular binding site. Besides selective P2X1 antagonists, compounds with ancillary P2X4 and/or P2X7 receptor inhibition were discovered. These compounds represent the first potent, non-acidic, allosteric P2X1 receptor antagonists reported to date.

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF OSTEOARTHRITIS

-

Paragraph 0029; 0030, (2013/03/28)

A pharmaceutical composition including 2-hydroxy-N—[3-(trifluoromethyl)phenyl]benzamide and used for treatment of osteoarthritis is revealed. The pharmaceutical composition inhibits tumor necrosis factor (TNF) induced interferon regulatory factor (IRF). The activated IRF stimulates chondrocytes to secret matrix metalloproteinases, inducible nitric oxide synthase (iNOS), aggrecanases, etc. This leads to loss of collagen II and further causes degradation of proteoglycan. By suppression of signaling pathways of interferon regulatory factor, symptoms are relieved and osteoarthritis is treated.

PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE OF SALICYLANILIDES FOR TREATMENT OF HEPATITIS VIRUSES

-

, (2012/05/07)

A new class of salicylanilides is described. These compounds show strong activity against hepatitis viruses.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 587-49-5